UCB partners with Harvard University to research neurology and autoimmune disorders and to develop antibodies against an undisclosed target to treat diabetes and metabolic disorders

Harvard University

U.S. / Academic

Research Partner

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

UCB S.A.

Belgium / Mid-Cap Biopharma ($1-$50 billion)

$7,999.8m on 06/24/2011 [market cap]

Research Partner

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced